IR Insights: Recapping Our 2025 Analyst Day
Earlier today, Moderna hosted its Analyst Day, which included presentations from management discussing Moderna's development and commercial strategy and key business considerations.
Members of our executive team sat down to provide a recap of the updates shared. Watch our latest IR Insights video below to hear more from our CEO Stéphane Bancel, President Stephen Hoge, and CFO Jamey Mock.
Forward-Looking Statements
This post and accompanying video contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s near-term strategy and anticipated commercial growth drivers, including geographic expansion and new product launches; Moderna’s ability to achieve up to 10% revenue growth in 2026; Moderna’s 2026 and 2027 expected GAAP operating expenses; Moderna’s ability to expand its seasonal vaccine franchise to up to six approved products by 2028; Moderna’s anticipated cash breakeven in 2028; anticipated clinical readouts in Moderna’s oncology pipeline; Moderna’s continued cost management and R&D prioritization and ability to reduce cash costs; Moderna’s balance sheet and 2025 projected year-end cash and investment balance; and anticipated milestones for Moderna's pipeline programs. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this post are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this post.